Romano G, Klima R, Feiguin F. TDP-43 prevents retrotransposon activation in the Drosophila motor system through regulation of Dicer-2 activity. BMC Biol. 2020;18:82 pubmed publisher

Liu E, Russ J, Cali C, Phan J, Amlie Wolf A, Lee E. Loss of Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons. Cell Rep. 2019;27:1409-1421.e6 pubmed publisher

Piracha Z, Kwon H, Saeed U, Kim J, Jung J, Chwae Y, et al. Sirtuin 2 Isoform 1 Enhances Hepatitis B Virus RNA Transcription and DNA Synthesis through the AKT/GSK-3β/β-Catenin Signaling Pathway. J Virol. 2018;92: pubmed publisher

Tu T, Budzinska M, Vondran F, Shackel N, Urban S. Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles. J Virol. 2018;92: pubmed publisher

Cui X, Yang X, Wang H, Rong X, Jing S, Xie Y, et al. Luteolin-7-O-Glucoside Present in Lettuce Extracts Inhibits Hepatitis B Surface Antigen Production and Viral Replication by Human Hepatoma Cells in Vitro. Front Microbiol. 2017;8:2425 pubmed publisher

Ryu D, Ahn Y, Ryu W, Windisch M. Development of a novel hepatitis B virus encapsidation detection assay by viral nucleocapsid-captured quantitative RT-PCR. Biotechniques. 2015;59:287-93 pubmed publisher

Hollenbaugh J, Schader S, Schinazi R, Kim B. Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells. Virology. 2015;485:313-21 pubmed publisher

Cheng Z, Sun G, Guo W, Huang Y, Sun W, Zhao F, et al. Inhibition of hepatitis B virus replication by quercetin in human hepatoma cell lines. Virol Sin. 2015;30:261-8 pubmed publisher

Díaz Carballo D, Acikelli A, Klein J, Jastrow H, Dammann P, Wyganowski T, et al. Therapeutic potential of antiviral drugs targeting chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elements. J Exp Clin Cancer Res. 2015;34:81 pubmed publisher

Casadellà M, Manzardo C, Noguera Julian M, Ferrer E, Domingo P, Perez Alvarez S, et al. Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. AIDS. 2015;29:1493-504 pubmed publisher

Sugimoto C, Hasegawa A, Saito Y, Fukuyo Y, Chiu K, Cai Y, et al. Differentiation Kinetics of Blood Monocytes and Dendritic Cells in Macaques: Insights to Understanding Human Myeloid Cell Development. J Immunol. 2015;195:1774-81 pubmed publisher

Li Q, Tso F, Kang G, Lu W, Li Y, Fan W, et al. Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice. J Acquir Immune Defic Syndr. 2015;69:519-27 pubmed publisher

Flax V, Adair L, Allen L, Shahab Ferdows S, Hampel D, Chasela C, et al. Plasma Micronutrient Concentrations Are Altered by Antiretroviral Therapy and Lipid-Based Nutrient Supplements in Lactating HIV-Infected Malawian Women. J Nutr. 2015;145:1950-7 pubmed publisher

Ngoma M, Misir A, Mutale W, Rampakakis E, Sampalis J, Elong A, et al. Efficacy of WHO recommendation for continued breastfeeding and maternal cART for prevention of perinatal and postnatal HIV transmission in Zambia. J Int AIDS Soc. 2015;18:19352 pubmed publisher

Chaves Valadão A, Abreu C, Dias J, Arantes P, Verli H, Tanuri A, et al. Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity. Molecules. 2015;20:11474-89 pubmed publisher

Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Hayashi T, Kohmoto M, et al. Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. J Interferon Cytokine Res. 2015;35:613-20 pubmed publisher

Zhu S, Zhong J, Ke Y, Xiao H, Ma L, Chen J, et al. Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma. Tumour Biol. 2015;36:6277-84 pubmed publisher

Ishida Y, Yamasaki C, Yanagi A, Yoshizane Y, Fujikawa K, Watashi K, et al. Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice. Am J Pathol. 2015;185:1275-85 pubmed publisher

Seki T, Suyama Kagitani A, Kawauchi Miki S, Miki S, Wakasa Morimoto C, Akihisa E, et al. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob Agents Chemother. 2015;59:2596-606 pubmed publisher

Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015;80:285-93 pubmed publisher

Zhang C, Ke W, Gao Y, Zhou S, Liu L, Ye X, et al. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China. Clin Drug Investig. 2015;35:197-209 pubmed publisher

Cui X, Cho Y, Song B. Influence of the basal core promoter and precore mutation on replication of hepatitis B virus and antiviral susceptibility of different genotypes. J Med Virol. 2015;87:601-8 pubmed publisher

Huang T, Yang C, Kuo Y, Chang Y, Yang L, Chou B, et al. Synthesis and anti-hepatitis B virus activity of C4 amide-substituted isosteviol derivatives. Bioorg Med Chem. 2015;23:720-8 pubmed publisher

Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312:2521-30 pubmed publisher

Abramson J, Chung R. Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma. JAMA. 2014;312:2505-7 pubmed publisher

Wu H, Zhang X, Zhang H, Zhang Q, Chen Z, Huang J, et al. In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors. AIDS Res Hum Retroviruses. 2015;31:260-70 pubmed publisher

Sprenger H, Langebeek N, Mulder P, Ten Napel C, Vriesendorp R, Hoepelman A, et al. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study. HIV Med. 2015;16:122-31 pubmed publisher

Moreira J. Barriers to simplified HIV treatment in low-resource settings. Lancet Infect Dis. 2014;14:1178-9 pubmed publisher

Murakami Y, Hayakawa M, Yano Y, Tanahashi T, Enomoto M, Tamori A, et al. Discovering novel direct acting antiviral agents for HBV using in silico screening. Biochem Biophys Res Commun. 2015;456:20-8 pubmed publisher

Alebouyeh M, Amini H. Rapid determination of lamivudine in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;975:40-4 pubmed publisher

Mistry N, Sereboe L, Oakeshott P. HIV testing in pregnancy. Sex Transm Infect. 2014;90:640 pubmed publisher

Rowland A, Mackenzie P, Miners J. Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition. Drug Metab Dispos. 2015;43:147-53 pubmed publisher

Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa Morimoto C, Suyama Kagitani A, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59:397-406 pubmed publisher

Bokhart M, Rosen E, Thompson C, Sykes C, Kashuba A, Muddiman D. Quantitative mass spectrometry imaging of emtricitabine in cervical tissue model using infrared matrix-assisted laser desorption electrospray ionization. Anal Bioanal Chem. 2015;407:2073-84 pubmed publisher

Sharon D, Chen M, Zhang G, Girgis S, Sis B, Graham D, et al. Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease. Liver Int. 2015;35:1442-50 pubmed publisher

Liu S, Wei W, Li Y, Lin X, Shi K, Cao X, et al. In vitro and in vivo anti-hepatitis B virus activities of the lignan nirtetralin B isolated from Phyllanthus niruri L. J Ethnopharmacol. 2014;157:62-8 pubmed publisher

Zheng Z, Lin B, Zhang J, Yang Z, Xie H, Zhou L, et al. Absolute lymphocyte count recovery at 1 month after transplantation predicts favorable outcomes of patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30:706-11 pubmed publisher

Zhang H, Pan C, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468-76 pubmed

Pirillo M, Scarcella P, Andreotti M, Jere H, Buonomo E, Sagno J, et al. Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. J Viral Hepat. 2015;22:289-96 pubmed publisher

Marais S, Wilkinson K, Lesosky M, Coussens A, Deffur A, Pepper D, et al. Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2014;59:1638-47 pubmed publisher

Powis K, Lockman S, Smeaton L, Hughes M, Fawzi W, Ogwu A, et al. Vitamin D insufficiency in HIV-infected pregnant women receiving antiretroviral therapy is not associated with morbidity, mortality or growth impairment in their uninfected infants in Botswana. Pediatr Infect Dis J. 2014;33:1141-7 pubmed publisher

McCarthy M. HIV is detected in child thought to have been cured. BMJ. 2014;349:g4614 pubmed publisher

Liu S, Wei W, Shi K, Cao X, Zhou M, Liu Z. In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from Phyllanthus niruri L. J Ethnopharmacol. 2014;155:1061-7 pubmed publisher

Peris Vicente J, Villareal Traver M, Casas Breva I, Carda Broch S, Esteve Romero J. A micellar liquid chromatography method for the quantification of abacavir, lamivudine and raltegravir in plasma. J Pharm Biomed Anal. 2014;98:351-5 pubmed publisher

Bilello J, Lallos L, McCarville J, La Colla M, Serra I, Chapron C, et al. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2014;58:4431-42 pubmed publisher

Weller S, Chen S, Borland J, Savina P, Wynne B, Piscitelli S. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr. 2014;66:393-8 pubmed publisher

Zhang H, Dai L, Wu Y, Yu X, Zhang Y, Guan R, et al. Evaluation of hepatocyteprotective and anti-hepatitis B virus properties of Cichoric acid from Cichorium intybus leaves in cell culture. Biol Pharm Bull. 2014;37:1214-20 pubmed

Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, et al. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial. Antivir Ther. 2014;19:269-76 pubmed publisher

Price A, Kayange M, Zaba B, Chimbwandira F, Jahn A, Chirwa Z, et al. Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study. Sex Transm Infect. 2014;90:309-14 pubmed publisher

Sarkar M, Terrault N. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology. 2014;60:448-51 pubmed publisher

Bhatt N, Barau C, Amin A, Baudin E, Meggi B, Silva C, et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. Antimicrob Agents Chemother. 2014;58:3182-90 pubmed publisher

Mishra D, Jain N, Rajoriya V, Jain A. Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine. J Pharm Pharmacol. 2014;66:1082-93 pubmed publisher

Cho J, Paik Y, Sohn W, Cho H, Gwak G, Choi M, et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut. 2014;63:1943-50 pubmed publisher

Fabrizi F, Mangano S, Stellato T, Martin P, Messa P. Lamivudine treatment for hepatitis B in dialysis population : case reports and literature review. Acta Gastroenterol Belg. 2013;76:423-8 pubmed

Tseng K, Chen C, Tsai H, Chang T, Chuang W, Hsu P, et al. Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study. Antivir Ther. 2014;19:755-64 pubmed publisher

Sehgal V, Verma P, Sharma S. HIV/AIDS Kaposi sarcoma: the Indian perspective. Skinmed. 2013;11:375-7 pubmed

Deng Y, Yoshida K, Jin Q, Murata M, Yamaguchi T, Tsuneyama K, et al. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol. 2014;176:102-11 pubmed publisher

Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann H, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980-8 pubmed publisher

Liao S, Fan S, Liu Q, Li C, Chen J, Li J, et al. In vitro evaluation of 9-(2-phosphonylmethoxyethyl)adenine ester analogues, a series of anti-HBV structures with improved plasma stability and liver release. Arch Pharm Res. 2014;37:1416-25 pubmed publisher

Grant P, Tierney C, Budhathoki C, Daar E, Sax P, Collier A, et al. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202. HIV Clin Trials. 2013;14:284-91 pubmed publisher

Huang Z, Zhao S, Huang Y, Dai X, Zhou R, Yi P, et al. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Clin Ther. 2013;35:1997-2006 pubmed publisher

Harzallah K, Haddad W, Haloues M, El Kossai I, Romdhane N, Abdallah H, et al. Pre-emptive treatment of hepatitis B infection by lamivudine in two Tunisian renal transplant recipients. Saudi J Kidney Dis Transpl. 2013;24:1195-8 pubmed publisher

Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807-18 pubmed publisher

Kim G, Lim Y, An J, Lee D, Shim J, Kim K, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325-32 pubmed publisher

Ye X, Su Q. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol. 2013;19:6665-78 pubmed publisher

Lian J, Zeng L, Chen J, Jia H, Zhang Y, Xiang D, et al. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol. 2013;19:6278-83 pubmed publisher

Raffi F, Jaeger H, Quiros Roldan E, Albrecht H, Belonosova E, Gatell J, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927-35 pubmed publisher

Mese S, Arikan M, Cakiris A, Abaci N, Gumus E, Kursun O, et al. Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients. J Gen Virol. 2013;94:2729-2738 pubmed publisher

Chao D, Hu K. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther. 2013;7:777-88 pubmed publisher

Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay K, et al. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. J Infect Dis. 2014;209:399-408 pubmed publisher

Pammi M, Arumainayagam J, Kumari B, Ahmed Jushuf I, Carlin E, Chandramani S, et al. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study). Int J Clin Pract. 2013;67:922-3 pubmed publisher

Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, et al. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology. 2014;59:89-97 pubmed publisher

Hamers R, Zaaijer H, Wallis C, Siwale M, Ive P, Botes M, et al. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013;64:174-82 pubmed publisher

Müller F, Konig J, Hoier E, Mandery K, Fromm M. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol. 2013;86:808-15 pubmed publisher

Wang L, Chen H, Fan C, Gong Z. Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection. J Med Virol. 2013;85:1907-12 pubmed publisher

Gupta Wright A, Wood R, Bekker L, Lawn S. Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service. J Acquir Immune Defic Syndr. 2013;64:261-70 pubmed publisher

Milosević I, Delic D, Lazarevic I, Pavlovic I, Korac M, Bojović K, et al. The significance of hepatitis B virus (HBV) genotypes for the disease and treatment outcome among patients with chronic hepatitis B in Serbia. J Clin Virol. 2013;58:54-8 pubmed publisher

Dai C, Tseng T, Wong G, Huang J, Wong V, Liu C, et al. Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. J Antimicrob Chemother. 2013;68:2332-8 pubmed publisher

Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, et al. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect. 2013;67:322-8 pubmed publisher

Peters P, McNicholl J, Raengsakulrach B, Wasinrapee P, Mueanpai F, Ratanasuwan W, et al. An evaluation of hepatitis B virus diagnostic methods and responses to antiretroviral therapy among HIV-infected women in Thailand. J Int Assoc Provid AIDS Care. 2013;12:349-53 pubmed publisher

Terrault N. Prophylaxis in HBV-infected liver transplant patients: end of the HBIG era?. Am J Gastroenterol. 2013;108:949-51 pubmed publisher

Kyaw N, Thanachartwet V, Kiertiburanakul S, Desakorn V, Chamnanchanunt S, Chierakul W, et al. Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand. Southeast Asian J Trop Med Public Health. 2013;44:232-43 pubmed

Wang J, He L, Chen Q. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir. Eur Rev Med Pharmacol Sci. 2013;17:1162-6 pubmed

Li Y. [Treatment of one advanced schistosomiasis patient with hepatitis B cirrhosis by lamivudine and adefovir dipivoxil]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2013;25:119-20 pubmed

Taverne B, Desclaux A, Koita Fall M, Delaporte E, Ndoye I. Antiretroviral drugs in Africa: a public health versus a market approach. J Acquir Immune Defic Syndr. 2013;63:e74-6 pubmed publisher

Zhang J, Perelson A. Contribution of follicular dendritic cells to persistent HIV viremia. J Virol. 2013;87:7893-901 pubmed publisher

Holmes D. Talk of HIV cure goes viral. Lancet Infect Dis. 2013;13:298-9 pubmed

Fung J, Chan S, Cheung C, Yuen M, Chok K, Sharr W, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013;108:942-8 pubmed publisher

Wang J, Shi J, Wu J, Huang X, Zhu M, Lou G. [Genotypes and evolution characteristics of three patients with poor response to initial treatment of Lamivudine and Adefovir dipivoxil for hepatitis]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012;26:474-6 pubmed

Kiage J, Heimburger D, Nyirenda C, Wellons M, Bagchi S, Chi B, et al. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis. 2013;12:50 pubmed publisher

Walker D, Patrick O Neill J, Tyson F, Walker V. The stress response resolution assay. I. Quantitative assessment of environmental agent/condition effects on cellular stress resolution outcomes in epithelium. Environ Mol Mutagen. 2013;54:268-80 pubmed publisher

Walker D, Nicklas J, Walker V. The stress response resolution assay. II. Quantitative assessment of environmental agent/condition effects on cellular stress resolution outcomes in epithelium. Environ Mol Mutagen. 2013;54:281-93 pubmed publisher

Chang M, Olsen S, Pichardo E, Stiles J, Rosenthal Cogan L, Brubaker W, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation. 2013;95:960-5 pubmed publisher

Shey M, Kongnyuy E, Alobwede S, Wiysonge C. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. Cochrane Database Syst Rev. 2013;:CD005481 pubmed publisher

Wang H, Ji Y, Yao G, Ma X, Xie Q, Pang H, et al. Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients. Eur Rev Med Pharmacol Sci. 2013;17:636-43 pubmed

Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky J. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology. 2013;58:890-901 pubmed publisher

Yaşar D, Suyani E, Ozenirler S, Sucak G. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report. Transplant Proc. 2013;45:833-4 pubmed publisher

Wang Y, Thongsawat S, Gane E, Liaw Y, Jia J, Hou J, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20:e37-46 pubmed publisher

Peveling Oberhag J, Herrmann E, Kronenberger B, Farnik H, Susser S, Sarrazin C, et al. Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs. J Viral Hepat. 2013;20:234-9 pubmed publisher

Seto W, Wong D, Fung J, Huang F, Lai C, Yuen M. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923-31 pubmed publisher

Healy S, Gupta S, Melvin A. HIV/HBV coinfection in children and antiviral therapy. Expert Rev Anti Infect Ther. 2013;11:251-63 pubmed publisher

Han Z, Shi Y, Zhu J, Chen Y, Yin F, Xia L, et al. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. J Viral Hepat. 2013;20 Suppl 1:58-64 pubmed publisher

Gane E, Patterson S, Strasser S, McCaughan G, Angus P. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl. 2013;19:268-74 pubmed publisher

Kumar V, Reddy B, Kumar B, Sreekanth K, Babu K. High throughput LC-MS/MS method for simultaneous determination of zidovudine, lamivudine and nevirapine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;921-922:9-14 pubmed publisher

Neumann Fraune M, Beggel B, Pfister H, Kaiser R, Verheyen J. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates. J Med Virol. 2013;85:775-9 pubmed publisher

. Toxicology and carcinogenesis studies of mixtures of 3'-azido-3'-deoxythymidine (AZT), lamivudine (3TC), nevirapine (NVP), and nelfinavir mesylate (NFV) (Cas Nos. 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (transplacental expos. Natl Toxicol Program Tech Rep Ser. 2013;:1-212 pubmed

Baran B, Soyer O, Ormeci A, Gokturk S, Evirgen S, Bozbey H, et al. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013;57:1790-6 pubmed publisher

Liang J, Tang Y, Wu F, Deng X. Entecavir versus lamivudine for the treatment of chronic hepatitis B: a systematic review. Pharmazie. 2012;67:883-90 pubmed

Jiang H, Wang J, Zhao W. Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2013;32:11-8 pubmed publisher

Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, et al. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis. PLoS ONE. 2012;7:e32789 pubmed publisher

Chen Y, Ju T. Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. Int J Infect Dis. 2012;16:e152-8 pubmed publisher

Zhong J, Li L, Wu L. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;:CD008713 pubmed publisher

Miyajima I, Sata M. [Lamivudine, adefovir dipivoxil]. Nihon Rinsho. 2011;69 Suppl 4:492-7 pubmed

Sheng Y, Liu J, Tong S, Hu H, Zhang D, Hu P, et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J. 2011;8:393 pubmed publisher

Rizzardini G, Zucchi P. Abacavir and lamivudine for the treatment of human immunodeficiency virus. Expert Opin Pharmacother. 2011;12:2129-38 pubmed publisher

Wiens A, Venson R, Correr C, Pontarolo R. Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B. Braz J Infect Dis. 2011;15:225-30 pubmed

Strauch S, Jantratid E, Dressman J, Junginger H, Kopp S, Midha K, et al. Biowaiver monographs for immediate release solid oral dosage forms: lamivudine. J Pharm Sci. 2011;100:2054-63 pubmed publisher

Ikeda F, Kobashi H, Yamamoto K. [Treatment of patients with lamivudine-resistant chronic hepatitis B]. Nihon Shokakibyo Gakkai Zasshi. 2011;108:196-201 pubmed

Damerow H, Yuen L, Wiegand J, Walker C, Bock C, Locarnini S, et al. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol. 2010;82:1850-8 pubmed publisher

Zhao S, Tang L, Fan X, Chen L, Zhou R, Dai X. Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review. Virol J. 2010;7:211 pubmed publisher

Katz L, Tur Kaspa R, Guy D, Paul M. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Cochrane Database Syst Rev. 2010;:CD006005 pubmed publisher

Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:147-59 pubmed publisher